Search

Your search keyword '"Kakunaga, Shigeki"' showing total 187 results
Start Over Author "Kakunaga, Shigeki"
187 results on '"Kakunaga, Shigeki"'

2. A case of pelvic EWSR1-PATZ1 fusion sarcoma treated with carbon ion radiotherapy

Author

Yagi, Toshinari, primary, Suzuki, Osamu, additional, Matsuoka, Haruki, additional, Shinyashiki, Kei, additional, Wakamatsu, Toru, additional, Tamiya, Hironari, additional, Suzuki, Rie, additional, Kakunaga, Shigeki, additional, Takenaka, Satoshi, additional, Hashii, Yoshiko, additional, Yoshida, Ken-ichi, additional, and Nakanishi, Katsuyuki, additional

Published
2024
Full Text
View/download PDF

4. The role of chemotherapy and radiotherapy in localized extraskeletal osteosarcoma

Author

Heng, Marilyn, Gupta, Abha, Chung, Peter W, Healey, John H, Vaynrub, Max, Rose, Peter S, Houdek, Matthew T, Lin, Patrick P, Bishop, Andrew J, Hornicek, Francis J, Chen, Yen-Lin, Lozano-Calderon, Santiago, Holt, Ginger E, Han, Ilkyu, Biau, David, Niu, Xiaohui, Bernthal, Nicholas M, Ferguson, Peter C, Wunder, Jay S, Group, Japanese Musculoskeletal Oncology, Ueda, Takafumi, Kakunaga, Shigeki, Kawai, Akira, Sugiura, Hideshi, Kidani, Teruki, Kunisasa, Toshiyuki, Ozaki, Toshifumi, Ae, Keisuke, Nagano, Akihito, Ohno, Takatoshi, Hiraoka, Koji, Yamamoto, Norio, Tsuchiya, Hiroyuki, Matsumoto, Yoshihiro, Yanagawa, Takashi, Nakayama, Robart, Morioka, Hideo, Kubo, Tadahiko, Simose, Shoji, Yamagami, Yoshiki, Yamamoto, Tetsuji, Kawasaki, Motohiro, Torigoe, Tomoaki, Yazawa, Yasuo, Akiyama, Toru, Gokita, Tabu, Manabe, Jun, Kaya, Mitsunori, Emori, Makoto, Nakamura, Tomoki, Matsumine, Akihiko, Sugihara, Shinsuke, Yokouchi, Masahiro, Komiya, Setsuro, Suehara, Yoshiyuki, Takagi, Tatsuya, Kawamoto, Teruya, Wasa, Junji, Yonemoto, Tsukasa, Ishii, Takeshi, Baba, Ichiro, Hoshi, Manabu, Hamada, Kenichiro, Naka, Norifumi, Sotobori, Tsukasa, Araki, Nobuhito, Okuma, Tomotake, Goto, Takahiro, Kobayashi, Hiroshi, Kawano, Hirotaka, Hosaka, Masami, Futani, Hiroyuki, Hiraga, Hiroaski, Nishida, Yoshihiro, Collaborative, Soft Tissue Osteosarcoma International, Griffin, Anthony, Razak, Albiruni R Abdul, Shultz, David Benjamin, Catton, Charles, Robinson, Steven, Patel, Shreyaskumar R, Lewis, Valerae O, Guadagnolo, B Ashleigh, DeLaney, Thomas, Wang, Haotong, Raskin, Kevin, Callan, Alexandra K, Henshaw, Robert, Isler, Marc, Mottard, Sophie, Chen, Wei-Ming, Traub, Frank, Chen, Tom Wei-Wu, Turcotte, Robert E, Davidson, Darin, Tunn, Per-Ulf, Loong, Herbert, Ghert, Michelle, Werier, Joel, and Clarkson, Paul

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Cancer, Patient Safety, Clinical Research, Adult, Aged, Aged, 80 and over, Female, Humans, Male, Middle Aged, Osteosarcoma, Prognosis, Retrospective Studies, Risk Factors, Survival Analysis, Young Adult, Extraskeletal osteosarcoma, Soft-tissue osteosarcoma, Chemotherapy, Radiotherapy, Radiation therapy, Japanese Musculoskeletal Oncology Group, Soft Tissue Osteosarcoma International Collaborative, Public Health and Health Services, Oncology & Carcinogenesis, Oncology and carcinogenesis
Abstract

PurposeThe role of chemotherapy (CT) and radiotherapy (RT) for management of extraskeletal osteosarcoma (ESOS) remains controversial. We examined disease outcomes for ESOS patients and investigated the association between CT/RT with recurrence and survival.Patients and methodsRetrospective review at 25 international sarcoma centers identified patients ≥18 years old treated for ESOS from 1971 to 2016. Patient/tumour characteristics, treatment, local/systemic recurrence, and survival data were collected. Kaplan-Meier survival and Cox proportional-hazards regression and cumulative incidence competing risks analysis were performed.Results370 patients with localized ESOS treated definitively with surgery presented with mainly deep tumours (n = 294, 80%). 122 patients underwent surgical resection alone, 96 (26%) also received CT, 70 (19%) RT and 82 (22%) both adjuvants. Five-year survival for patients with localized ESOS was 56% (95% CI 51%-62%). Almost half of patients (n = 173, 47%) developed recurrence: local 9% (35/370), distant 28% (102/370) or both 10% (36/370). Considering death as a competing event, there was no significant difference in cumulative incidence of local or systemic recurrence between patients who received CT, RT, both or neither (local p = 0.50, systemic p = 0.69). Multiple regression Cox analysis showed a significant association between RT and decreased local recurrence (HR 0.46 [95% CI 0.26-0.80], p = 0.01).ConclusionAlthough the use of RT significantly decreased local recurrences, CT did not decrease the risk of systemic recurrence, and neither CT, nor RT nor both were associated with improved survival in patients with localized ESOS. Our results do not support the use of CT; however, adjuvant RT demonstrates benefit in patients with locally resectable ESOS.

Published
2020

5. Efficacy and safety of nivolumab monotherapy in patients with unresectable clear cell sarcoma and alveolar soft part sarcoma (OSCAR Trial/NCCH1510)

Author

Nishikawa, Tadaaki, Kakunaga, Shigeki, Tamura, Kenji, Ando, Masashi, Ozaki, Toshifumi, Kawai, Akira, Ueda, Takafumi, Kawasaki, Mamiko, Tomatsuri, Sawako, Okamura, Nobuko, Kamikura, Masahisa, Hamada, Akinobu, Yoshida, Akihiko, Hirakawa, Akihiro, Shibata, Taro, Nakamura, Kenichi, and Yonemori, Kan

Subjects
*NIVOLUMAB, *IMMUNE checkpoint inhibitors, *SARCOMA, *OVERALL survival, *PROGRESSION-free survival, *RENAL cell carcinoma
Abstract

ABSTRACT Background Methods Results Conclusions Clear cell sarcoma (CCS) and alveolar soft part sarcoma (ASPS) are rare, and standard systemic therapy is not established except for sunitinib in ASPS. It is known that CCS and ASPS have a common biological feature of melanoma and Xp11.2/TFE3 translocation renal cell carcinoma, and immune‐checkpoint inhibitors (ICIs) are effective in these tumors. The authors conducted a phase 2 trial to evaluate the efficacy and safety of nivolumab for CCS and ASPS.The number of patients expected to be enrolled was 15–25 and was determined based on the Bayesian design. The primary end point was the confirmed objective response rate (ORR) according to the central review and the secondary end points included ORR, progression‐free survival (PFS), overall survival (OS), and safety.A total of 26 patients (CCS, 12; ASPS, 14) were enrolled. Efficacy and safety were analyzed on 25 and 26 patients, respectively. The minimum number of responses required for a positive conclusion regarding the efficacy was four. However, only one patient (4.0%) with ASPS had a partial response. Complete response, stable disease, progression disease, and not evaluable were 0%, 60%, 32%, and 4.0%, respectively. Adverse events of grade 3 or 4 occurred in 57.7% (15 of 26). The median PFS was 4.9 months (95% confidence interval [CI], 3.7–8.6 months) and the median OS was 15.8 months (95% CI, 8.2–not reached).The primary end point of the ORR was not met for CCS and ASPS on the central review. Further studies are needed to evaluate ICIs in patients with ASPS. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

6. Supplementary Table S2 from Safety and Efficacy of NY-ESO-1 Antigen-Specific T-Cell Receptor Gene-Transduced T Lymphocytes in Patients with Synovial Sarcoma: A Phase I/II Clinical Trial

Author

Kawai, Akira, primary, Ishihara, Mikiya, primary, Nakamura, Tomoki, primary, Kitano, Shigehisa, primary, Iwata, Shintaro, primary, Takada, Kohichi, primary, Emori, Makoto, primary, Kato, Koji, primary, Endo, Makoto, primary, Matsumoto, Yoshihiro, primary, Kakunaga, Shigeki, primary, Sato, Eiichi, primary, Miyahara, Yoshihiro, primary, Morino, Kunihiko, primary, Tanaka, Shinya, primary, Takahashi, Shuichi, primary, Matsuo, Fujio, primary, Matsumine, Akihiko, primary, Kageyama, Shinichi, primary, and Ueda, Takafumi, primary

Published
2023
Full Text
View/download PDF

7. Supplementary Figure S1 from Safety and Efficacy of NY-ESO-1 Antigen-Specific T-Cell Receptor Gene-Transduced T Lymphocytes in Patients with Synovial Sarcoma: A Phase I/II Clinical Trial

Author

Kawai, Akira, primary, Ishihara, Mikiya, primary, Nakamura, Tomoki, primary, Kitano, Shigehisa, primary, Iwata, Shintaro, primary, Takada, Kohichi, primary, Emori, Makoto, primary, Kato, Koji, primary, Endo, Makoto, primary, Matsumoto, Yoshihiro, primary, Kakunaga, Shigeki, primary, Sato, Eiichi, primary, Miyahara, Yoshihiro, primary, Morino, Kunihiko, primary, Tanaka, Shinya, primary, Takahashi, Shuichi, primary, Matsuo, Fujio, primary, Matsumine, Akihiko, primary, Kageyama, Shinichi, primary, and Ueda, Takafumi, primary

Published
2023
Full Text
View/download PDF

8. Data from Safety and Efficacy of NY-ESO-1 Antigen-Specific T-Cell Receptor Gene-Transduced T Lymphocytes in Patients with Synovial Sarcoma: A Phase I/II Clinical Trial

Author

Kawai, Akira, primary, Ishihara, Mikiya, primary, Nakamura, Tomoki, primary, Kitano, Shigehisa, primary, Iwata, Shintaro, primary, Takada, Kohichi, primary, Emori, Makoto, primary, Kato, Koji, primary, Endo, Makoto, primary, Matsumoto, Yoshihiro, primary, Kakunaga, Shigeki, primary, Sato, Eiichi, primary, Miyahara, Yoshihiro, primary, Morino, Kunihiko, primary, Tanaka, Shinya, primary, Takahashi, Shuichi, primary, Matsuo, Fujio, primary, Matsumine, Akihiko, primary, Kageyama, Shinichi, primary, and Ueda, Takafumi, primary

Published
2023
Full Text
View/download PDF

9. Safety and Efficacy of NY-ESO-1 Antigen-Specific T-Cell Receptor Gene-Transduced T Lymphocytes in Patients with Synovial Sarcoma: A Phase I/II Clinical Trial

Author

Kawai, Akira, primary, Ishihara, Mikiya, additional, Nakamura, Tomoki, additional, Kitano, Shigehisa, additional, Iwata, Shintaro, additional, Takada, Kohichi, additional, Emori, Makoto, additional, Kato, Koji, additional, Endo, Makoto, additional, Matsumoto, Yoshihiro, additional, Kakunaga, Shigeki, additional, Sato, Eiichi, additional, Miyahara, Yoshihiro, additional, Morino, Kunihiko, additional, Tanaka, Shinya, additional, Takahashi, Shuichi, additional, Matsuo, Fujio, additional, Matsumine, Akihiko, additional, Kageyama, Shinichi, additional, and Ueda, Takafumi, additional

Published
2023
Full Text
View/download PDF

10. O16-2 Phase I trial of NY-ESO-1 TCR-T cell therapy combined with nanoparticulate vaccine but without lymphodepletion for STS

Author

Ishihara, Mikiya, primary, Nishida, Yoshihiro, additional, Kitano, Shigehisa, additional, Kawai, Akira, additional, Harada, Naozumi, additional, Miyahara, Yoshihiro, additional, Hattori, Hiroyoshi, additional, Takada, Kohichi, additional, Emori, Makoto, additional, Kakunaga, Shigeki, additional, Endo, Makoto, additional, Matsumoto, Yoshihiro, additional, Sasada, Tetsuro, additional, Sato, Eiichi, additional, Yamada, Tomomi, additional, Matsumine, Akihiko, additional, Nagata, Yasuhiro, additional, Kageyama, Shinichi, additional, and Shiku, Hiroshi, additional

Published
2023
Full Text
View/download PDF

14. Survival analysis of elderly patients with osteosarcoma

Author

Imura, Yoshinori, Takenaka, Satoshi, Kakunaga, Shigeki, Nakai, Takaaki, Wakamatsu, Toru, Outani, Hidetatsu, Tanaka, Takaaki, Tamiya, Hironari, Oshima, Kazuya, Hamada, Kenichiro, Naka, Norifumi, Araki, Nobuhito, Kudawara, Ikuo, Ueda, Takafumi, and Yoshikawa, Hideki

Published
2019
Full Text
View/download PDF

17. Local surgery feasibility and safety after carbon ion radiotherapy for primary bone sarcomas

Author

Sabe, Hideaki, primary, Outani, Hidetatsu, additional, Imura, Yoshinori, additional, Takami, Haruna, additional, Nakai, Takaaki, additional, Takenaka, Satoshi, additional, Kakunaga, Shigeki, additional, Tamiya, Hironari, additional, Wakamatsu, Toru, additional, Nakai, Sho, additional, Demizu, Yusuke, additional, Imai, Reiko, additional, and Okada, Seiji, additional

Published
2023
Full Text
View/download PDF

20. A phase 1 trial of NY‐ESO ‐1‐specific TCR ‐engineered T‐cell therapy combined with a lymph node‐targeting nanoparticulate peptide vaccine for the treatment of advanced soft tissue sarcoma

Author

Ishihara, Mikiya, primary, Nishida, Yoshihiro, additional, Kitano, Shigehisa, additional, Kawai, Akira, additional, Muraoka, Daisuke, additional, Momose, Fumiyasu, additional, Harada, Naozumi, additional, Miyahara, Yoshihiro, additional, Seo, Naohiro, additional, Hattori, Hiroyoshi, additional, Takada, Kohichi, additional, Emori, Makoto, additional, Kakunaga, Shigeki, additional, Endo, Makoto, additional, Matsumoto, Yoshihiro, additional, Sasada, Tetsuro, additional, Sato, Eiichi, additional, Yamada, Tomomi, additional, Matsumine, Akihiko, additional, Nagata, Yasuhiro, additional, Watanabe, Takashi, additional, Kageyama, Shinichi, additional, and Shiku, Hiroshi, additional

Published
2023
Full Text
View/download PDF

25. Development and external validation of nomograms predicting distant metastases and overall survival after neoadjuvant chemotherapy and surgery for patients with nonmetastatic osteosarcoma: A multi-institutional study

Author

Ogura, Koichi, Fujiwara, Tomohiro, Yasunaga, Hideo, Matsui, Hiroki, Jeon, Dae-Geun, Cho, Wan Hyeong, Hiraga, Hiroaki, Ishii, Takeshi, Yonemoto, Tsukasa, Kamoda, Hiroto, Ozaki, Toshifumi, Kozawa, Eiji, Nishida, Yoshihiro, Morioka, Hideo, Hiruma, Toru, Kakunaga, Shigeki, Ueda, Takafumi, Tsuda, Yusuke, Kawano, Hirotaka, and Kawai, Akira

Published
2015
Full Text
View/download PDF

26. 18F-Fluorodeoxyglucose Positron Emission Tomography Is Useful in the Evaluation of Prognosis in Retroperitoneal Sarcoma

Author

Wakamatsu, Toru, primary, Imura, Yoshinori, additional, Tamiya, Hironari, additional, Yagi, Toshinari, additional, Yasuda, Naohiro, additional, Nakai, Sho, additional, Nakai, Takaaki, additional, Outani, Hidetatsu, additional, Hamada, Kenichiro, additional, Kakunaga, Shigeki, additional, Araki, Nobuhito, additional, Ueda, Takafumi, additional, and Takenaka, Satoshi, additional

Published
2021
Full Text
View/download PDF

27. Short-term clinical outcomes of Kyocera Modular Limb Salvage System designed cementless stems for the endoprosthetic reconstruction of lower extremities: a Japanese Musculoskeletal Oncology Group multi-institutional study.

Author

Tsukushi, Satoshi, Nishida, Yoshihiro, Hirose, Takeshi, Nakata, Eiji, Nakagawa, Rumi, Nakamura, Tomoki, Imanishi, Jungo, Nagano, Akihito, Tamiya, Hironari, Ueda, Takafumi, and Japanese Musculoskeletal Oncology Group (JMOG), Ikuta, Kunihiro, Kawai, Akira, Kunisada, Toshiyuki, Nakayama, Robert, Torigoe, Tomoaki, Takenaka, Satoshi, Kakunaga, Shigeki, Kawano, Hirotaka, and Shirai, Toshiharu

Subjects
LIMB salvage, SYSTEMS design, BONE remodeling, RADIOSTEREOMETRY, REOPERATION, TREATMENT effectiveness, PERIPROSTHETIC fractures
Abstract

Background: The high rate of aseptic loosening of cemented stems has led to their frequent use in endoprosthetic reconstruction. However, problems, such as stem breakage and stress shielding at the insertion site, remain. The Japanese Musculoskeletal Oncology Group (JMOG) has developed Kyocera Modular Limb Salvage System (KMLS) cementless stems with a unique tapered press-fit and short fixation design. This study aimed to clarify the short-term postoperative outcomes of this prosthesis and validate the stem design.Methods: One hundred cases of KMLS cementless stems (51 male patients; median age, 49 years; mean follow-up period, 35 months), with a minimum follow-up of 2 years, for the proximal femur (PF), distal femur (DF), and proximal tibia were prospectively registered for use. Prosthesis survival, complication rates, postoperative functional, and radiographical evaluation were analyzed. Complications or failures after insertion of the KMLS endoprostheses were classified into five types and functional results were analyzed according to the MSTS scoring system at postoperative 1 year. The diaphyseal interface and anchorage were graded by the ISOLS system at postoperative 2 years.Results: The overall prosthesis survival rates at 2 and 4 years were 88.2 and 79.6%, respectively. The prosthesis-specific survival rate excluding infection and tumor recurrence was 90.2 and 87.9%, respectively. Younger age (p = 0.045) and primary tumor (p = 0.057) were associated with poor prognosis of prosthesis-specific survival excluding infection and tumor recurrence. Complications were observed in 31 patients, 13 patients underwent revision surgery. The mean MSTS functional score at 1 year postoperatively was 68%. Early implant loosening was significantly more common in the DF (p = 0.006) and PF/DF straight stem (p = 0.038). The ISOLS radiographic evaluation at 2 years after surgery revealed good bone remodeling and anchorage in most cases (bone remodeling: 90% / excellent and good, anchorage: 97% / excellent and good).Conclusions: Tumor endoprosthesis long-term fixation to the diaphysis of the lower extremity remains challenging. The KMLS cementless stem with a unique tapered press fit design showed good short-term results in maintaining bone stock. To prevent early loosening, a curved stem should be used in PF and DF, but long-term follow-up is necessary. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

29. Giant cell tumor of bone – Analysis of 213 cases involving extra‐craniofacial bones

Author

Konishi, Eiichi, primary, Outani, Hidetatsu, additional, Mano, Masayuki, additional, Nagata, Shigenori, additional, Shirai, Toshiharu, additional, Naka, Norifumi, additional, Hori, Yumiko, additional, Takenaka, Satoshi, additional, Haga, Hironori, additional, Toguchida, Junya, additional, Kakunaga, Shigeki, additional, Kuwae, Yuko, additional, Hoshi, Manabu, additional, Inoue, Takeshi, additional, Aono, Masanari, additional, Morinaga, Yukiko, additional, and Nakashima, Yasuaki, additional

Published
2021
Full Text
View/download PDF

33. Successful pazopanib treatment of undifferentiated pleomorphic sarcoma with coamplification of PDGFRA, VEGFR2 and KIT: A case report.

Author

Matsuoka, Haruki, Yoshida, Ken-Ichi, Nakai, Sho, Suzuki, Rie, Imura, Yoshinori, Takami, Haruna, Watanabe, Makiyo, Wakamatsu, Toru, Tamiya, Hironari, Outani, Hidetatsu, Yagi, Toshinari, Kakunaga, Shigeki, and Takenaka, Satoshi

Abstract

Undifferentiated pleomorphic sarcoma (UPS) is a high-grade, aggressive soft tissue sarcoma (STS) with a poor prognosis, and no definitive or effective treatment is currently available for it. Pazopanib, an orally available multiple tyrosine kinase inhibitor, has been approved for the treatment of advanced STS. The present study documents the case of a 51-year-old man with advanced UPS with coamplification of platelet-derived growth factor receptor A (PDGFRA), vascular endothelial growth factor receptor 2 (VEGFR2) and stem cell factor receptor (KIT) genes. The patient exhibited a marked and sustained response to pazopanib. The patient presented with a retroperitoneal tumour with pancreatic head lymph node metastasis, and bone metastases in the second/fifth thoracic vertebrae and left femur. Based on the histological analysis of the retroperitoneal tumour and femoral mass, the patient was diagnosed with UPS. Palliative radiation therapy was administered to the left femur and second/fifth thoracic vertebrae to prevent fractures. After radiation therapy, the patient achieved a partial response after eight courses of doxorubicin. A comprehensive genomic profiling analysis (FoundationOne® CDx) revealed coamplification of PDGFRA, VEGFR2 and KIT genes. Hence, pazopanib was initiated as a second-line treatment. Notably, the retroperitoneal tumour shrank, and no new lesions developed for 3 years after the initiation of pazopanib treatment. This response suggests that the coamplification of PDGFRA, VEGFR2 and KIT may predict favourable outcomes in response to pazopanib. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

34. Correction: Inhibition of cell movement and proliferation by cell–cell contact-induced interaction of Necl-5 with nectin-3

Author

Fujito, Tsutomu, Ikeda, Wataru, Kakunaga, Shigeki, Minami, Yukiko, Kajita, Mihoko, Sakamoto, Yasuhisa, Monden, Morito, and Takai, Yoshimi

Subjects
Nectins, Correction, Down-Regulation, Cell Biology, Clathrin, Endocytosis, Neoplasm Proteins, Mice, Antigens, Neoplasm, Cell Movement, Cell Adhesion, NIH 3T3 Cells, Animals, RNA, Small Interfering, Cell Adhesion Molecules, Cell Proliferation
Abstract

Immunoglobulin-like Necl-5/Tage4/poliovirus receptor (PVR)/CD155, originally identified as the PVR, has been shown to be up-regulated in cancer cells and to enhance growth factor-induced cell movement and proliferation. In addition, Necl-5 heterophilically trans-interacts with nectin-3, a cell-cell adhesion molecule known to form adherens junctions in cooperation with cadherin. We show here that Necl-5 was down-regulated from cell surface upon cell-cell contacts in NIH3T3 cells. This down-regulation of Necl-5 was initiated by its interaction with nectin-3 and was mainly mediated by clathrin-dependent endocytosis. Then, the down-regulation of Necl-5 induced in this way reduced movement and proliferation of NIH3T3 cells. These results indicate that the down-regulation of Necl-5 induced by its interaction with nectin-3 upon cell-cell contacts may be at least one mechanism underlying contact inhibition of cell movement and proliferation.

Published
2020

37. A long‐term follow‐up study of extracorporeal irradiated autografts in limb salvage surgery for malignant bone and soft tissue tumors: A minimum follow‐up of 10 years after surgery

Author

Outani, Hidetatsu, primary, Takenaka, Satoshi, additional, Hamada, Kenichiro, additional, Imura, Yoshinori, additional, Kakunaga, Shigeki, additional, Tamiya, Hironari, additional, Wakamatsu, Toru, additional, Naka, Norifumi, additional, Ueda, Takafumi, additional, and Araki, Nobuhito, additional

Published
2020
Full Text
View/download PDF

39. The role of chemotherapy and radiotherapy in localized extraskeletal osteosarcoma

Author

Heng, Marilyn, primary, Gupta, Abha, additional, Chung, Peter W., additional, Healey, John H., additional, Vaynrub, Max, additional, Rose, Peter S., additional, Houdek, Matthew T., additional, Lin, Patrick P., additional, Bishop, Andrew J., additional, Hornicek, Francis J., additional, Chen, Yen-Lin, additional, Lozano-Calderon, Santiago, additional, Holt, Ginger E., additional, Han, Ilkyu, additional, Biau, David, additional, Niu, Xiaohui, additional, Bernthal, Nicholas M., additional, Ferguson, Peter C., additional, Wunder, Jay S., additional, Ueda, Takafumi, additional, Kakunaga, Shigeki, additional, Kawai, Akira, additional, Sugiura, Hideshi, additional, Kidani, Teruki, additional, Kunisasa, Toshiyuki, additional, Ozaki, Toshifumi, additional, Ae, Keisuke, additional, Nagano, Akihito, additional, Ohno, Takatoshi, additional, Hiraoka, Koji, additional, Yamamoto, Norio, additional, Tsuchiya, Hiroyuki, additional, Matsumoto, Yoshihiro, additional, Yanagawa, Takashi, additional, Nakayama, Robart, additional, Morioka, Hideo, additional, Kubo, Tadahiko, additional, Simose, Shoji, additional, Yamagami, Yoshiki, additional, Yamamoto, Tetsuji, additional, Kawasaki, Motohiro, additional, Torigoe, Tomoaki, additional, Yazawa, Yasuo, additional, Akiyama, Toru, additional, Gokita, Tabu, additional, Manabe, Jun, additional, Kaya, Mitsunori, additional, Emori, Makoto, additional, Nakamura, Tomoki, additional, Matsumine, Akihiko, additional, Sugihara, Shinsuke, additional, Yokouchi, Masahiro, additional, Komiya, Setsuro, additional, Suehara, Yoshiyuki, additional, Takagi, Tatsuya, additional, Kawamoto, Teruya, additional, Wasa, Junji, additional, Yonemoto, Tsukasa, additional, Ishii, Takeshi, additional, Baba, Ichiro, additional, Hoshi, Manabu, additional, Hamada, Kenichiro, additional, Naka, Norifumi, additional, Sotobori, Tsukasa, additional, Araki, Nobuhito, additional, Okuma, Tomotake, additional, Goto, Takahiro, additional, Kobayashi, Hiroshi, additional, Kawano, Hirotaka, additional, Hosaka, Masami, additional, Futani, Hiroyuki, additional, Hiraga, Hiroaski, additional, Nishida, Yoshihiro, additional, Griffin, Anthony, additional, Razak, Albiruni R.Abdul, additional, Shultz, David Benjamin, additional, Catton, Charles, additional, Robinson, Steven, additional, Patel, Shreyaskumar R., additional, Lewis, Valerae O., additional, Guadagnolo, B. Ashleigh, additional, DeLaney, Thomas, additional, Wang, Haotong, additional, Raskin, Kevin, additional, Callan, Alexandra K., additional, Henshaw, Robert, additional, Isler, Marc, additional, Mottard, Sophie, additional, Chen, Wei-Ming, additional, Traub, Frank, additional, Chen, Tom Wei-Wu, additional, Turcotte, Robert E., additional, Davidson, Darin, additional, Tunn, Per-Ulf, additional, Loong, Herbert, additional, Ghert, Michelle, additional, Werier, Joel, additional, Clarkson, Paul, additional, and Abraham, John A., additional

Published
2020
Full Text
View/download PDF

41. Symptomatic Venous Thromboembolism in Patients with Malignant Bone and Soft Tissue Tumors: A Prospective Multicenter Cohort Study.

Author

Iwata, Shintaro, Kawai, Akira, Ueda, Takafumi, Ishii, Takeshi, Japanese Musculoskeletal Oncology Group (JMOG), Yonemoto, Tsukasa, Kamoda, Hiroto, Suzuki, Yoshihisa, Kikuta, Kazutaka, Imanishi, Jungo, Okubo, Taketo, Yazawa, Yasuo, Sotobori, Tsukasa, Murata, Hiroaki, Ozaki, Toshifumi, Kunisada, Toshiyuki, Fujiwara, Tomohiro, Kakunaga, Shigeki, Hiraoka, Koji, and Hamada, Tetsuya

Abstract

Background: A prospective cohort study was conducted to determine the incidence and risk factors of symptomatic venous thromboembolism (sVTE) during the perioperative period in patients with malignant bone and soft tissue tumors. Methods: Patients with newly diagnosed primary malignant bone and soft tissue tumors for whom definitive surgery was planned were consecutively registered among 27 tertiary hospitals specializing in musculoskeletal oncology. Clinicopathological information on each patient was collected prospectively, and careful follow-up was conducted for 6 months after surgery. The study endpoint was the occurrence of sVTE, including deep vein thrombosis (DVT) and pulmonary embolism (PE). Results: Eleven of 929 patients developed sVTE, including 8 patients with DVT, 2 with PE, and 1 with both, making the incidence of sVTE 1.18%. The median time until the development of sVTE after tumor resection was 11 days, ranging from − 7 to 95 days. Multiple logistic regression analyses revealed that ischemic heart disease as a comorbidity, maximum tumor diameter exceeding 8 cm, and elevated preoperative platelet count were independent risk factors for sVTE. Conclusions: The incidence of sVTE in this series of patients with bone and soft tissue sarcomas was 1.18%, which was relatively lower than in previous retrospective studies. We identified the risk factors for sVTE specific to patients with malignant bone and soft tissue tumors, and these included ischemic heart disease, tumor size, and elevation of the preoperative platelet count. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

42. Favorable outcomes of localized synovial sarcoma patients with a high utilization rate of neoadjuvant and/or adjuvant chemotherapy

Author

Outani, Hidetatsu, primary, Kakunaga, Shigeki, additional, Hamada, Kenichiro, additional, Takenaka, Satoshi, additional, Imura, Yoshinori, additional, Nagata, Shigenori, additional, Tanaka, Takaaki, additional, Tamiya, Hironari, additional, Oshima, Kazuya, additional, Naka, Norifumi, additional, Kudawara, Ikuo, additional, Araki, Nobuhito, additional, Ueda, Takafumi, additional, and Yoshikawa, Hideki, additional

Published
2019
Full Text
View/download PDF

43. Clinical outcomes of patients with epithelioid sarcomas: impact and management of nodal metastasis

Author

Outani, Hidetatsu, primary, Imura, Yoshinori, additional, Tanaka, Takaaki, additional, Takenaka, Satoshi, additional, Oshima, Kazuya, additional, Hamada, Kenichiro, additional, Kakunaga, Shigeki, additional, Joyama, Susumu, additional, Naka, Norifumi, additional, Kudawara, Ikuo, additional, Ueda, Takafumi, additional, Araki, Nobuhito, additional, and Yoshikawa, Hideki, additional

Published
2017
Full Text
View/download PDF

45. Results from phase I/II study of NY-ESO-1-specific TCR gene-transduced T cell therapy (TBI-1301, mipetresgene autoleucel) in patients with advanced synovial sarcoma.

Author

Kawai, Akira, Ishihara, Mikiya, Nakamura, Tomoki, Kitano, Shigehisa, Iwata, Shintaro, Takada, Kohichi, Emori, Makoto, Kato, Koji, Endo, Makoto, Matsumoto, Yoshihiro, Kakunaga, Shigeki, Sato, Eiichi, Miyahara, Yoshihiro, Morino, Kunihiko, Tanaka, Shinya, Takahashi, Shuichi, Matsumine, Akihiko, Kageyama, Shinichi, and Ueda, Takafumi

Published
2023
Full Text
View/download PDF

46. Comparison of clinical and functional outcome between surgical treatment and carbon ion radiotherapy for pelvic chondrosarcoma

Author

Outani, Hidetatsu, primary, Hamada, Kenichiro, additional, Imura, Yoshinori, additional, Oshima, Kazuya, additional, Sotobori, Tsukasa, additional, Demizu, Yusuke, additional, Kakunaga, Shigeki, additional, Joyama, Susumu, additional, Imai, Reiko, additional, Okimoto, Tomoaki, additional, Naka, Norifumi, additional, Kudawara, Ikuo, additional, Ueda, Takafumi, additional, Araki, Nobuhito, additional, Kamada, Tadashi, additional, and Yoshikawa, Hideki, additional

Published
2015
Full Text
View/download PDF

50. A novel type of EWS–CHOP fusion gene in myxoid liposarcoma

Author

Matsui, Yoshito, primary, Ueda, Takafumi, additional, Kubo, Takahiro, additional, Hasegawa, Tadashi, additional, Tomita, Yasuhiko, additional, Okamoto, Mina, additional, Myoui, Akira, additional, Kakunaga, Shigeki, additional, Yasui, Natsuo, additional, and Yoshikawa, Hideki, additional

Published
2006
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results